AAPL281.74-2.04 (-0.72%) ▼|ABBV254.31+0.96 (+0.38%) ▲|ABT92.71-1.41 (-1.50%) ▼|ACN124.74-4.24 (-3.29%) ▼|ADBE206.43+3.70 (+1.83%) ▲|AMAT694.64+67.80 (+10.82%) ▲|AMD539.49+17.91 (+3.43%) ▲|AMGN360.55+2.22 (+0.62%) ▲|AMT168.67-6.92 (-3.94%) ▼|AMZN240.14+7.45 (+3.20%) ▲|AVGO372.45+7.43 (+2.04%) ▲|AXP340.88+0.52 (+0.15%) ▲|BA214.69-2.56 (-1.18%) ▼|BAC57.88+0.00 (+0.00%) ▲|BKNG182.41+0.95 (+0.52%) ▲|BLK950.17-14.54 (-1.51%) ▼|BMY58.56+1.04 (+1.81%) ▲|BNY143.80+0.24 (+0.17%) ▲|BRK-B496.00-2.66 (-0.53%) ▼|C142.49+0.73 (+0.52%) ▲|CAT1,033.19+35.72 (+3.58%) ▲|CL92.40+0.33 (+0.36%) ▲|CMCSA24.22+1.05 (+4.53%) ▲|COF202.28-1.72 (-0.84%) ▼|COP104.20-1.76 (-1.66%) ▼|COST946.68-5.86 (-0.62%) ▼|CRM157.93-0.44 (-0.28%) ▼|CSCO117.70+3.93 (+3.45%) ▲|CVS103.58-0.76 (-0.73%) ▼|CVX168.47-2.59 (-1.51%) ▼|DE626.63+13.39 (+2.18%) ▲|DHR192.78-3.41 (-1.74%) ▼|DIS98.63-0.16 (-0.16%) ▼|DUK128.33-0.07 (-0.05%) ▼|EMR142.82-0.67 (-0.47%) ▼|FDX325.40+6.87 (+2.16%) ▲|GD348.07+1.36 (+0.39%) ▲|GE373.71+4.71 (+1.28%) ▲|GEV1,102.51+57.34 (+5.49%) ▲|GILD126.33-1.55 (-1.21%) ▼|GM77.34-0.76 (-0.97%) ▼|GOOG351.28+16.59 (+4.96%) ▲|GOOGL353.65+16.26 (+4.82%) ▲|GS1,020.21+0.60 (+0.06%) ▲|HD350.81+1.95 (+0.56%) ▲|HON227.80-15.61 (-6.41%) ▼|IBM278.00+6.37 (+2.35%) ▲|INTC131.72+3.40 (+2.65%) ▲|INTU266.40-1.32 (-0.49%) ▼|ISRG405.97+1.70 (+0.42%) ▲|JNJ258.51+3.85 (+1.51%) ▲|JPM329.39+0.34 (+0.10%) ▲|KO82.65+0.02 (+0.02%) ▲|LIN511.06-8.56 (-1.65%) ▼|LLY1,229.93+21.81 (+1.81%) ▲|LMT502.07-5.33 (-1.05%) ▼|LOW219.65-2.83 (-1.27%) ▼|LRCX410.91+31.82 (+8.39%) ▲|MA509.64+10.62 (+2.13%) ▲|MCD267.18-2.58 (-0.96%) ▼|MDLZ60.15-0.64 (-1.05%) ▼|MDT80.93-0.05 (-0.06%) ▼|META562.60+12.35 (+2.24%) ▲|MMM162.43-1.58 (-0.96%) ▼|MO74.05+0.26 (+0.35%) ▲|MRK129.38+0.72 (+0.56%) ▲|MS211.72-0.31 (-0.15%) ▼|MSFT368.57-4.40 (-1.18%) ▼|MU1,145.28+12.95 (+1.14%) ▲|NEE88.66+0.10 (+0.11%) ▲|NFLX73.78-0.03 (-0.04%) ▼|NKE41.48+0.73 (+1.79%) ▲|NOW99.97+1.63 (+1.66%) ▲|NVDA194.97+2.44 (+1.27%) ▲|ORCL147.76-0.77 (-0.52%) ▼|PEP138.68-2.71 (-1.92%) ▼|PFE24.37+0.08 (+0.33%) ▲|PG148.45-0.57 (-0.38%) ▼|PLTR115.70+2.77 (+2.45%) ▲|PM182.87+2.10 (+1.16%) ▲|QCOM188.72-0.67 (-0.35%) ▼|RTX187.33-0.66 (-0.35%) ▼|SBUX104.06-0.54 (-0.52%) ▼|SCHW90.55-0.12 (-0.13%) ▼|SO96.75-0.41 (-0.42%) ▼|SPG227.56+0.67 (+0.30%) ▲|T21.82-0.90 (-3.96%) ▼|TMO506.42-6.61 (-1.29%) ▼|TMUS173.97-8.71 (-4.77%) ▼|TSLA411.84+32.13 (+8.46%) ▲|TXN285.48+0.06 (+0.02%) ▲|UBER75.50-0.70 (-0.92%) ▼|UNH419.82-8.07 (-1.89%) ▼|UNP272.70+4.35 (+1.62%) ▲|UPS108.01-0.13 (-0.12%) ▼|USB61.28+0.37 (+0.61%) ▲|V341.65+5.42 (+1.61%) ▲|VZ44.10-2.44 (-5.24%) ▼|WFC83.51-0.35 (-0.42%) ▼|WMT114.60-1.09 (-0.94%) ▼|XOM136.06-0.48 (-0.35%) ▼|AAPL281.74-2.04 (-0.72%) ▼|ABBV254.31+0.96 (+0.38%) ▲|ABT92.71-1.41 (-1.50%) ▼|ACN124.74-4.24 (-3.29%) ▼|ADBE206.43+3.70 (+1.83%) ▲|AMAT694.64+67.80 (+10.82%) ▲|AMD539.49+17.91 (+3.43%) ▲|AMGN360.55+2.22 (+0.62%) ▲|AMT168.67-6.92 (-3.94%) ▼|AMZN240.14+7.45 (+3.20%) ▲|AVGO372.45+7.43 (+2.04%) ▲|AXP340.88+0.52 (+0.15%) ▲|BA214.69-2.56 (-1.18%) ▼|BAC57.88+0.00 (+0.00%) ▲|BKNG182.41+0.95 (+0.52%) ▲|BLK950.17-14.54 (-1.51%) ▼|BMY58.56+1.04 (+1.81%) ▲|BNY143.80+0.24 (+0.17%) ▲|BRK-B496.00-2.66 (-0.53%) ▼|C142.49+0.73 (+0.52%) ▲|CAT1,033.19+35.72 (+3.58%) ▲|CL92.40+0.33 (+0.36%) ▲|CMCSA24.22+1.05 (+4.53%) ▲|COF202.28-1.72 (-0.84%) ▼|COP104.20-1.76 (-1.66%) ▼|COST946.68-5.86 (-0.62%) ▼|CRM157.93-0.44 (-0.28%) ▼|CSCO117.70+3.93 (+3.45%) ▲|CVS103.58-0.76 (-0.73%) ▼|CVX168.47-2.59 (-1.51%) ▼|DE626.63+13.39 (+2.18%) ▲|DHR192.78-3.41 (-1.74%) ▼|DIS98.63-0.16 (-0.16%) ▼|DUK128.33-0.07 (-0.05%) ▼|EMR142.82-0.67 (-0.47%) ▼|FDX325.40+6.87 (+2.16%) ▲|GD348.07+1.36 (+0.39%) ▲|GE373.71+4.71 (+1.28%) ▲|GEV1,102.51+57.34 (+5.49%) ▲|GILD126.33-1.55 (-1.21%) ▼|GM77.34-0.76 (-0.97%) ▼|GOOG351.28+16.59 (+4.96%) ▲|GOOGL353.65+16.26 (+4.82%) ▲|GS1,020.21+0.60 (+0.06%) ▲|HD350.81+1.95 (+0.56%) ▲|HON227.80-15.61 (-6.41%) ▼|IBM278.00+6.37 (+2.35%) ▲|INTC131.72+3.40 (+2.65%) ▲|INTU266.40-1.32 (-0.49%) ▼|ISRG405.97+1.70 (+0.42%) ▲|JNJ258.51+3.85 (+1.51%) ▲|JPM329.39+0.34 (+0.10%) ▲|KO82.65+0.02 (+0.02%) ▲|LIN511.06-8.56 (-1.65%) ▼|LLY1,229.93+21.81 (+1.81%) ▲|LMT502.07-5.33 (-1.05%) ▼|LOW219.65-2.83 (-1.27%) ▼|LRCX410.91+31.82 (+8.39%) ▲|MA509.64+10.62 (+2.13%) ▲|MCD267.18-2.58 (-0.96%) ▼|MDLZ60.15-0.64 (-1.05%) ▼|MDT80.93-0.05 (-0.06%) ▼|META562.60+12.35 (+2.24%) ▲|MMM162.43-1.58 (-0.96%) ▼|MO74.05+0.26 (+0.35%) ▲|MRK129.38+0.72 (+0.56%) ▲|MS211.72-0.31 (-0.15%) ▼|MSFT368.57-4.40 (-1.18%) ▼|MU1,145.28+12.95 (+1.14%) ▲|NEE88.66+0.10 (+0.11%) ▲|NFLX73.78-0.03 (-0.04%) ▼|NKE41.48+0.73 (+1.79%) ▲|NOW99.97+1.63 (+1.66%) ▲|NVDA194.97+2.44 (+1.27%) ▲|ORCL147.76-0.77 (-0.52%) ▼|PEP138.68-2.71 (-1.92%) ▼|PFE24.37+0.08 (+0.33%) ▲|PG148.45-0.57 (-0.38%) ▼|PLTR115.70+2.77 (+2.45%) ▲|PM182.87+2.10 (+1.16%) ▲|QCOM188.72-0.67 (-0.35%) ▼|RTX187.33-0.66 (-0.35%) ▼|SBUX104.06-0.54 (-0.52%) ▼|SCHW90.55-0.12 (-0.13%) ▼|SO96.75-0.41 (-0.42%) ▼|SPG227.56+0.67 (+0.30%) ▲|T21.82-0.90 (-3.96%) ▼|TMO506.42-6.61 (-1.29%) ▼|TMUS173.97-8.71 (-4.77%) ▼|TSLA411.84+32.13 (+8.46%) ▲|TXN285.48+0.06 (+0.02%) ▲|UBER75.50-0.70 (-0.92%) ▼|UNH419.82-8.07 (-1.89%) ▼|UNP272.70+4.35 (+1.62%) ▲|UPS108.01-0.13 (-0.12%) ▼|USB61.28+0.37 (+0.61%) ▲|V341.65+5.42 (+1.61%) ▲|VZ44.10-2.44 (-5.24%) ▼|WFC83.51-0.35 (-0.42%) ▼|WMT114.60-1.09 (-0.94%) ▼|XOM136.06-0.48 (-0.35%) ▼|
25.3 C
New York
Tuesday, June 30, 2026

Tag: cancer

newssourceFORcompanyinformationcontent1releasesmarket

Portage Biotech and Compedica Stock-for-Stock Exchange

Portage Biotech and Compedica Stock-for-Stock Exchange

Nord Anglia Education Awards Over $155,000 in 2025 ‘Social Impact Grants’ to Student-Led Global Projects Advancing UN SDGs

Student-led projects driving innovation in AI, healthcare, sustainability, and inclusive education across Nord Anglia's global schools LONDON, June 9, 2025 /PRNewswire/ -- Leading international schools organisation...

CancerVax Targets Liver Cancers to Further Showcase Flexibility of Its Universal Platform

Using AI machine learning, the Company discovers distinct biomarkers for detecting certain rare liver cancers that have stem cell characteristics and will include them as additional indications in its preclinical program 
Using AI machine learning, the Company discovers distinct biomarkers for detecting certain rare liver cancers that have stem cell characteristics and will include them as additional indications in its preclinical program

Tech Legend Bill Atkinson Logs Off at 74

Back in November 1983, I had my first run-in with Bill Atkinson while reporting on the soon-to-launch Macintosh. You know, back when the personal...

Dupixent® (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color

Atopic dermatitis is a chronic disease that disproportionately impacts communities of color

Over 4,400 Riders Embark on Ride to Conquer Cancer, Canada’s Largest Athletic Fundraiser, Raising Over $20.61 Million for Life-Saving Research

Riders Begin 2-Day, 200+ KM Journey in Support of The Princess Margaret for a World Free From the Fear of Cancer TORONTO, June 7, 2025...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. – URGN

NEW YORK, June 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of UroGen Pharma Ltd. ("UroGen" or the "Company") (NASDAQ: URGN). Such investors...

The British Medical Journal Publishes Study Results on Sacituzumab Tirumotecan for Previously Treated EGFR-Mutant Advanced NSCLC

CHENGDU, China, June 6, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", 6990.HK) today announced that results from its registrational study (OptiTROP-Lung03) evaluating...

URGN Investors with Large Losses Should Contact Robbins LLP for Information About the Class Action Lawsuit Against UroGen Pharma Ltd.

Robbins LLP is Investigating Allegations that UroGen Pharma Ltd. (URGN) Failed to Conduct a Proper Trial for its Lead Drug Candidate

UroGen Pharma Ltd. (URGN) Faces Securities Class Action Amid FDA’s Briefing Document and Subsequent ODAC Vote Against UGN-102– Hagens Berman

URGN Investors with Losses Encouraged to Contact Hagens Berman 
URGN Investors with Losses Encouraged to Contact Hagens Berman

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WOBURN, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to newly hired non-executive employees.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsCancer

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers